FindTrial
Sign In

DSP-7888 Dosing Emulsion

DRUG3 trials

Sponsors

Sumitomo Pharma America, Inc.

Conditions

Acute Myeloid LeukemiaFallopian Tube CancerGlioblastomaGlioblastoma MultiformeMelanomaMyelodysplastic SyndromesNon-Small Cell Lung CancerOvarian Cancer

Phase 1

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
CompletedNCT02498665
Sumitomo Pharma America, Inc.Acute Myeloid Leukemia, Glioblastoma Multiforme, Melanoma +6
Start: 2015-11-30End: 2018-09-30Updated: 2023-11-14
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
TerminatedNCT03311334
Sumitomo Pharma America, Inc.Fallopian Tube Cancer, Platinum-resistant Ovarian Cancer (PROC), Primary Peritoneal Cancer +3
Start: 2017-12-14End: 2022-11-29Updated: 2024-04-18

Phase 3

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
CompletedNCT03149003
Sumitomo Pharma America, Inc.Glioblastoma
Start: 2017-12-08End: 2021-08-30Updated: 2023-11-15

Related Papers

Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).
Journal of Clinical Oncology2023-06-011 citations
Abstract CT135: Preliminary safety and efficacy of DSP-7888 plus nivolumab (NIV) or pembrolizumab (PEM) in patients (pts) with advanced solid tumors (ASTs): A phase (Ph) 1b/2 open-label study
Cancer Research2022-06-151 citations
A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies
Scientific Reports2021-11-1614 citations
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
Targeted Oncology2021-05-0329 citations
A phase Ib/II, multicenter, open-label study of DSP-7888 dosing emulsion in combination with immune checkpoint inhibitors (CPI) nivolumab or pembrolizumab in adult patients (pts) with advanced solid tumors, including platinum-resistant ovarian cancer (PROC).
Journal of Clinical Oncology2020-05-202 citations
A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma.
Journal of Clinical Oncology2018-05-207 citations